C. Cohen

发表

The cost effectiveness of combination antiretroviral therapy for HIV disease.

M C Weinstein, A D Paltiel, M. Weinstein, 2001, The New England journal of medicine.

Improving adherence to antiretroviral therapy.

R. Remien, E. Daar, C. Cohen, 2003, The AIDS reader.

Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.

K. Freedberg, A. Tosteson, C. Cohen, 1991, Journal of acquired immune deficiency syndromes.

CD4+ count-guided interruption of antiretroviral treatment.

J Darbyshire, N Clumeck, J Hoy, 2006, The New England journal of medicine.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

J. Gatell, A. Phillips, B. Grund, 2008, The Journal of infectious diseases.

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

Michael Ames, Kurt Hertogs, K. Hertogs, 2002, AIDS.

Tolerability of Enteric‐Coated Didanosine Capsules Compared With Didanosine Tablets in Adults With HIV Infection

C. Cohen, E. Coakley, L. Kunches, 2001, Journal of Acquired Immune Deficiency Syndromes.

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

J. Montaner, D. Kuritzkes, S. Walmsley, 2003, The New England journal of medicine.

Low-Level Viremia in HIV-1 Infection: Consequences and Implications for Switching to a New Regimen

C. Cohen, 2009, HIV clinical trials.

Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients

C. Cohen, J. Maa, R. Campo, 2010, International journal of STD & AIDS.

Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV

J. Meyers, K. Davis, C. Cohen, 2013, BMJ Open.

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis.

K. Freedberg, C. Cohen, T. W. Barber, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Pilot Study of Saquinavir and Lopinavir/Ritonavir Twice Daily in Protease Inhibitor-Naive HIV-Positive Patients

C. Cohen, Danielle M Gordon, L. Jackson-Pope, 2005, HIV clinical trials.

Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients

C. Cohen, E. Dejesus, D. Pearce, 2007, Journal of the International Association of Physicians in AIDS Care.

Editorial comment: impact of darunavir for salvage therapy.

C. Cohen, B. Boyle, 2007, The AIDS reader.

Increasing Treatment Adherence in the Correctional Setting: Current Efforts to Simplify Protease Inhibitor Dosing Regimens

C. Cohen, P. Piliero, Orlando H. Pile, 2000 .

Entry and Fusion Inhibitors: an Update

John Moore, C. Hogan, C. Cohen, 2002 .

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects

David E. Martin, C. Cohen, J. Lalezari, 2011, Journal of acquired immune deficiency syndromes.

Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives?

B. Clotet, C. Kovacs, C. Katlama, 2009, AIDS research and therapy.

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

P. Volberding, J. Gallant, M. Saag, 2002, AIDS research and human retroviruses.

Evaluation of Efficacy, Safety, Pharmacokinetics, and Adherence in HIV-1—Infected, Antiretroviral-Naïve Patients Treated with Ritonavir-Boosted Atazanavir Plus Fixed-Dose Tenofovir DF/Emtricitabine Given Once Daily

D. Ward, R. Ebrahimi, C. Cohen, 2008, HIV clinical trials.

Antiretroviral treatment update from the 17th International AIDS Conference.

P. Sax, I. Frank, C. Cohen, 2008, The AIDS reader.

Inhaled pentamidine and prevention of Pneumocystis pneumonia.

K. Freedberg, A. Tosteson, B. Hirschel, 1991, New England Journal of Medicine.

HIV Clinical Trials: Important Concepts and Questions

M. Hughes, D. Kuritzkes, P. Sax, 2005 .

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks

S. Staszewski, M. Johnson, Jesse Green, 2003, HIV clinical trials.

Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens

K. White, C. Cohen, A. Cheng, 2013, HIV clinical trials.

Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling study

K. Melbourne, J. Baker, C. Cohen, 2022, Frontiers in Immunology.

Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Double‐Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir)

D. Greenblatt, C. Cohen, M. Rhee, 2010, Journal of clinical pharmacology.

Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.

C. Cohen, 2005, The AIDS reader.

Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015

R. Schooley, E. Maltezos, Tak-chiu Wu, 2017, Open forum infectious diseases.

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results

K. White, P. Sax, A. Zolopa, 2013, Journal of acquired immune deficiency syndromes.

Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).

R. Redfield, B. Ha, C. Cohen, 2009, AIDS Research and Human Retroviruses.

Once-Daily Abacavir/Lamivudine/Zidovudine plus Tenofovir for the Treatment of HIV-1 Infection in Antiretroviral-NaïveSubjects: A 48-Week Pilot Study

R. Redfield, B. Ha, C. Cohen, 2006, HIV clinical trials.

Successful HIV treatment: lessons learned.

C. Cohen, 2006, Journal of managed care pharmacy : JMCP.

Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

C. Cohen, S. Talbird, A. Brogan, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness

Elena Losina, Calvin Cohen, M. Weinstein, 2001, Annals of Internal Medicine.

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

K. Tashima, S. Swindells, C. Cohen, 2005, BMC infectious diseases.

Low-Dose Daily Subcutaneous Interleukin-2 in Combination with Highly Active Antiretroviral Therapy in HIV + Patients: A Randomized Controlled Trial

Kendall A. Smith, R. Murphy, C. Cohen, 2000, HIV clinical trials.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

R Rode, M Salgo, D. Ho, 1999, AIDS.

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study

J. van Lunzen, A. Rieger, A. Antinori, 2016, AIDS.

Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

Brian P. Kearney, Calvin Cohen, Edwin DeJesus, 2006, Journal of acquired immune deficiency syndromes.

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

K. White, J. van Lunzen, R. Ebrahimi, 2014, AIDS.

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

H. Stellbrink, A. Lazzarin, P. Williams, 2013, AIDS.

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

B. Clotet, K. Ruxrungtham, M. Johnson, 2011, The Lancet.

A. LaMarca, C. Cohen, E. Dejesus, 2010, HIV clinical trials.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

K. White, P. Sax, A. Zolopa, 2012, The Lancet.

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials

B. Clotet, M. Johnson, M. Saag, 2012, Journal of acquired immune deficiency syndromes.

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients

A. Zolopa, J. Gallant, C. Cohen, 2012 .

Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living.

C. Cohen, M. Recny, E. Nelson, 2002, AIDS patient care and STDs.

Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.

K. White, C. Orkin, C. Cohen, 2014, AIDS patient care and STDs.

A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results

K. White, P. Sax, A. Zolopa, 2014, Journal of acquired immune deficiency syndromes.

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease

Calvin Cohen, John Leonard, Clement Maurath, 1998, The Lancet.

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.

C Maurath, R Rode, J. Leonard, 1998, Lancet.

STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults

K. White, C. Cohen, D. Wohl, 2012 .

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

R. Haubrich, B. Clotet, M. Markowitz, 2007, The Lancet.

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

Joel E Gallant, Calvin Cohen, Edwin DeJesus, 2003, AIDS.

Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection.

C. Cohen, E. Coakley, L. Kunches, 2001 .

Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients: 24-Week Results of POWER 3

C. Katlama, C. Cohen, J. Molina, 2007, Journal of acquired immune deficiency syndromes.

HIV Drug Therapy in the Americas Congress, 13 – 15 June 2013, São Paulo, Brazil

M. Lederman, D. Kuritzkes, K. White, 2013, Journal of the International AIDS Society.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

A. Phillips, J. Lundgren, W. El-Sadr, 2008, Annals of internal medicine.

Retroviral Rebound Syndrome after Cessation of Suppressive Antiretroviral Therapy in Three Patients with Chronic HIV Infection

C. Cohen, T. Hooton, D. Spach, 2000, Annals of Internal Medicine.

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

A. Gładysz, W. J. Fessel, C. Cohen, 2005, Current medical research and opinion.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

S. Chuck, C. Cohen, B. Kearney, 2011, AIDS.

Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy

J. Lundgren, J. Neaton, B. Grund, 2016, PloS one.

Once-daily antiretroviral therapies for HIV infection: Consensus statement of an Advisory Committee of the International Association of Physicians in AIDS Care

K. Squires, I. Frank, P. Tebas, 2002, Journal of the International Association of Physicians in AIDS Care.

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I)

K. Squires, P. Tebas, C. Cohen, 2000, AIDS.

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment

C. Cohen, S. Esser, Don E. Smith, 2016, AIDS care.

Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.

M. Weinstein, K. Freedberg, E. Losina, 2002, Archives of internal medicine.

A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease

D. Revicki, C. Cohen, P. Jiang, 1998, AIDS.

Jesse Green, N. Wintfeld, C. Cohen, 2004, Journal of acquired immune deficiency syndromes.

Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future

J. Montaner, C. Cohen, B. Nosyk, 2012, AIDS research and treatment.

Ritonavir-boosted protease inhibitors, Part 1: strategies for balancing efficacy with effects on lipids.

C. Cohen, 2005, The AIDS reader.

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients

C. Cohen, M. de Béthune, D. Berger, 2009, AIDS.

Pilot Study of a Novel Short-Cycle Antiretroviral Treatment Interruption Strategy: 48-Week Results of the Five-Days-On, Two-Days-Off (FOTO) Study

C. Cohen, Karen McLaughlin, A. Colson, 2007, HIV clinical trials.

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

G. D. Miralles, C. Cohen, M. Greenberg, 2005, The Journal of infectious diseases.

First‐line Treatment in HIV: Many Paths to Success

C. Cohen, 2003, Journal of acquired immune deficiency syndromes.

Virological Outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in Antiretroviral-Naive HIV-1-Infected Participants with Baseline HIV-1 RNA ≥1,000,000 Copies/ml: A Post Hoc Analysis of Phase III Clinical Trials

K. White, P. Sax, M. Das, 2018, Antiviral therapy.

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.

J. Montaner, B. Clotet, D. Kuritzkes, 2007, AIDS patient care and STDs.

The ARTEMIS trial: once-daily darunavir/ritonavir in the management of treatment-naive, HIV-infected patients

C. Cohen, 2009 .

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis

D. Ward, C. Cohen, C. Hicks, 2007, AIDS.

Antiretroviral therapy: the "when to start" debates.

C. Cohen, Calvin J Cohen, Brian A Boyle, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study.

K. Hertogs, W. Verbiest, B. Larder, 2001, AIDS.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic

Henrik Nielsen, L. Mathiesen, C. Leen, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores

R. Shafer, A. Zolopa, D. Kempf, 2008, Antimicrobial Agents and Chemotherapy.

Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults

H. Stellbrink, A. Lazzarin, P. Williams, 2011 .

Controversies in AIDS treatment. Proceedings from CME conference sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Question and answer session.

W. El-Sadr, M. Saag, J. Currier, 1998, AIDS patient care and STDs.

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

S. Chuck, C. Cohen, A. Mathias, 2011, AIDS.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir

B. Ha, C. Cohen, J. Horton, 2009, The Journal of antimicrobial chemotherapy.

From Adherence to Outcomes: Impact of Benefit Design on the HIV Patient

C. Cohen, R. A. Zabinski, Schumarry H. Chao, 2006, Journal of Managed Care Pharmacy : JMCP.

O214 The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy

D. Skiest, C. Cohen, J. Garb, 2008 .

Short‐term Safety and Tolerability of a Once‐Daily Fixed‐Dose Abacavir‐Lamivudine Combination versus Twice‐Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study

C. Cohen, P. Brachman, S. Schneider, 2008, Pharmacotherapy.

Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future

J. Montaner, C. Cohen, B. Nosyk, 2012, AIDS research and treatment.

D. Ward, K. Mounzer, M. Gottlieb, 2011, HIV clinical trials.

Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study

K. Mounzer, D. Skiest, C. Cohen, 2012 .